Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 61

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 61
---
(4,314,481)(1,152,437)(10,713,647)(5,799,795)Total research and development direct program costs641,668 1,539,276 2,674,324 7,202,681 Indirect costs:Personnel-related (including stock-based compensation)1,168,085 1,429,180 3,869,767 4,394,329 Other indirect costs38,848 58,236 238,044 218,413 Contra R&D expenses(673,433)(344,920)(1,880,824)(846,357)Total research and development indirect costs533,500 1,142,496 2,226,987 3,766,385 General and administrative2,499,242 2,041,268 7,186,272 7,159,979 Other operating expenses— — — 7,674 Total segment operating expenses3,674,410 4,723,040 12,087,583 18,136,719 Loss from operations(3,672,148)(4,681,349)(12,081,066)(18,063,288)Sale of royalty and milestone rights, net— — — 20,379,376 Interest expense213,171 227,573 615,754 654,613 Interest income(319,147)(194,354)(445,804)(428,120)Other income (expense), net3,406 12,067 (293,460)636,796 Net (loss) income$(3,562,766)$(4,702,501)$(11,957,556)$1,452,799 (1) For the three and nine months ended September 30, 2025, amount also includes expenses related to DARE to PLAY Sildenafil Cream.

13.    SUBSEQUENT EVENTS

Sales of Common StockSubsequent to September 30, 2025, the Company sold 360,000 shares of its common stock under its purchase agreement with Lincoln Park for aggregate gross proceeds of approximately $0.7 million, resulting in aggregate proceeds of approximately $0.7 million net of commissions and other offering expenses of approximately $29,000. For a discussion of the purchase agreement, see Note 4, Stockholder's Equity. Receipt of Payment Under 2021 DARE-LARC1